GlobalData on MSN
Edwards solidifies TAVR dominance in long-term trial readout
The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.
PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...
Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...
The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...
Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...
Investor's Business Daily on MSN
Edwards Jumps On Beat-And-Raise, Announces CFO Transition
Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback